237 studies found for:    AKT1
Show Display Options
Rank Status Study
1 Recruiting Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Conditions: Advanced Solid Malignancy;   Safety and Tolerability;   Pharmacokinetics;   Pharmacodynamics;   Tumour Response;   Advanced or Metastatic Breast Cancer;   Ovarian Cancer;   Cervical Cancer;   Endometrial Cancer;   PIK3CA;   AKT1;   ER+;   HER2+
Intervention: Drug: AZD5363
2 Recruiting Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
Condition: Neoplasms
Intervention: Drug: BAY1125976
3 Completed
Has Results
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
4 Enrolling by invitation A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
Condition: Schizophrenia
Intervention:
5 Enrolling by invitation Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism
Conditions: Aging;   Sleep Restriction;   Circadian Disruption
Interventions: Behavioral: Circadian Disruption;   Behavioral: Sleep Restriction;   Behavioral: Control
6 Completed A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)
Condition: Advanced Cancer
Interventions: Drug: Comparator: MK-8033;   Drug: Comparator: MK-8033 +/- omeprazole
7 Active, not recruiting Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Condition: Malignant Neoplasm
Interventions: Drug: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
8 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
9 Recruiting Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
Condition: Cardiovascular Abnormalities
Intervention: Drug: Sirolimus
10 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
11 Active, not recruiting Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Akt inhibitor MK2206;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis
12 Active, not recruiting A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Sarcoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
13 Active, not recruiting Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Drug: temsirolimus;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
14 Active, not recruiting A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Conditions: Acute Lymphoblastic Leukemia;   Leukemia, Myelocytic, Acute;   Chronic Myelogenous Leukemia With Crisis of Blast Cells
Intervention: Drug: BEZ235
15 Recruiting Molecular Phenotype Changes and Personalized Treatment for CRPC
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel & Prednisone;   Drug: DP & Targeted drugs;   Drug: cisplatin & Etoposide;   Drug: EP & Targeted drugs
16 Recruiting A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: RAD001
17 Completed
Has Results
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
Conditions: Cowden's Disease;   Hamartoma Syndrome, Multiple
Interventions: Radiation: fludeoxyglucose F 18;   Drug: sirolimus;   Other: Clinical Videography
18 Unknown  The Roles of Neutrophil Elastase in Lung Cancer
Conditions: Lung Cancer;   Chronic Obstructive Pulmonary Diseases
Intervention:
19 Recruiting Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment
Condition: Malignant Solid Neoplasms
Interventions: Drug: Nilotinib (400 mg BID);   Drug: Everolimus (10 mg QD);   Drug: Sorafenib (400 mg BID);   Drug: Lapatinib (1500 mg QD);   Drug: Pazopanib (800 mg QD)
20 Completed MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Leukemias of Ambiguous Lineage;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Aggressive NK-cell Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Myeloid/NK-cell Acute Leukemia;   Noncutaneous Extranodal Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: Akt inhibitor MK2206;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years